FDA Broadens Vemlidy Indication for Pediatric Chronic HBV Treatment
Gilead Sciences, Inc. has announced the U.S. Food and Drug Administration’s (FDA) approval of the supplemental new drug application...
Jon Napitupulu
Gilead and Xilio Enter Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have entered into an exclusive license agreement to develop and commercialize XTX301,...
European Commission Approves Keytruda® Plus Chemotherapy for Resectable NSCLC
Merck announced that the European Commission (EC) has approved KEYTRUDA, its anti-PD-1 therapy, for use in combination with platinum-containing...
BMS’s KRYSAL-12 Trial Shows Promise for Krazati in KRASG12C-Mutated NSCLC
Bristol Myers Squibb has announced significant outcomes from its Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) in patients with...
AN2 Therapeutics Resumes Phase 2/3 Trial for EBO-301
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to creating treatments for rare, chronic, and significant infectious diseases, announced...
SecondWave Systems Secures $3M Additional Financing to Advance Ultrasound-Based Anti-Inflammatory Therapy
SecondWave Systems, Inc., an innovative company at the forefront of bio-ultrasonic medicine development, is making significant strides in creating...
Photopharmics Initiates Largest Phototherapy Trial for Parkinson’s Disease
PhotoPharmics, in partnership with the Center for Health + Technology (CHeT) at the University of Rochester Medical Center (URMC),...
Trisalus Life Sciences Technology Spotlighted in SIR Annual Scientific Meeting
TriSalus Life Sciences® Inc., an oncology company specializing in novel delivery technologies combined with immunotherapy for liver and pancreatic...
Volastra Therapeutics Forms New Partnerships to Advance KIF18A Inhibitors in Cancer
Volastra Therapeutics, a clinical-stage biotechnology company at the forefront of developing cancer treatments targeting chromosomal instability (CIN), has announced...
BMS Enhances Health Equity Grant Initiatives for Better Health Outcomes
Bristol Myers Squibb (BMY) has launched a $1.8 million initiative to advance health equity by addressing the social determinants...